In draft guidance published today NICE recommends peginterferon alfa in combination with ribavirin as an option for treating chronic hepatitis C in children and young people.. Hepatitis C is a blood-borne virus that infects the liver. Children and young people get the disease primarily from their mothers at birth. If the virus is not cleared from the body, either naturally or through drugs to treat it, an acute infection (defined as the first six months following initial infection) can progress to chronic hepatitis C (long term infection, lasting more than six months). Chronic hepatitis C infection increases the risk of scarring of the liver (fibrosis and cirrhosis), liver failure and liver cancer. Peginterferon alfa-2a (Pegasys, Roche Products) and peginterferon alfa-2b (ViraferonPeg, Merck Sharp and Dohme (MSD)), in combination with ribavirin are the only treatments currently licensed in the UK for the treatment of chronic hepatitis C in children and adolescents.. Professor Carole Longson, ...
Published: Nov 11, 2014 8:02 a.m. ET. - High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease - BOSTON, Nov 11, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, +0.55% today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals. These data will be presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting2014) in Boston. Chronic hepatitis C patients with advanced liver disease are among the most difficult to cure and traditionally have had limited or no treatment options, said Norbert Bischofberger, PhD, Executive Vice President ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals. These data will be presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2014) in Boston. Chronic hepatitis C patients with advanced liver disease are among the most difficult to cure and traditionally have had limited or no treatment options, said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer, Gilead Sciences. The data presented this week demonstrate that Harvoni provides high cure ...
TY - JOUR. T1 - Daclatasvir for the treatment of chronic hepatitis C virus infection. AU - Temesgen, Zelalem. AU - Rizza, Stacey. PY - 2015/5/1. Y1 - 2015/5/1. N2 - Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.. AB - Daclatasvir ...
New treatments for genotype 1 chronic hepatitis C – focus on simeprevir Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir – one of the second-generation HCV NS3/4A protease inhibitors – in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice. This review summarizes the mechanism of action of simeprevir and the results of clinical trials of simeprevir and peginterferon plus ribavirin for HCV genotype 1 patients. In general, the simeprevir and peginterferon plus ribavirin treatment is highly effective and its adverse events are similar to those of peginterferon plus ribavirin only, the exception being
Inclusion criteria:. 1a. For treatment-naïve patients: no prior therapy with interferon, peginterferon, or ribavirin for acute or chronic hepatitis C infection. 1b. For treatment-experienced patients: confirmed virological failure during or after combination treatment with an approved dose of alfa-2a or alfa-2b peginterferon combined with ribavirin; such patients must have received at least 12 weeks of therapy with a 90 day washout period prior to screening and must have documentation of medical history prior to enrolment in 1220.2 2. Age 18 years or older 3. Signed informed consent form prior to trial participation 4. Male or female with documented hysterectomy or menopausal female with last menstrual period at least 6 months prior to screening 5. Chronic hepatitis C infection of genotype 1, diagnosed by positive HCV serology test (HCV Ab positive) or detectable HCV RNA at least 6 months prior to screening 6. HCV viral load ,= 100,000 IU/mL at screening 7. TSH and T4 within normal limits or ...
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. In the present study, we examined how ITPA and IL28B genotypes have clinical impacts on treatment-induced hematotoxicities and treatment response in HCV-infected patients treated with peginterferon plus ribavirin. ITPA genotypes (rs1127354 and rs6051702) and IL28B genotype (rs8099917) were determined by TaqMan SNP assay. We compared clinical background, treatment course and treatment response in terms of these genotypes. Only IL28B rs8099917 major type could predict sustained virological response. ITPA rs1127354 major type leads to significantly greater ribavirin-induced anemia than ITPA rs1127354 minor type between days 0 and 84. We noticed that IL28B rs8099917 minor genotype was associated with higher reduction of neutrophils and
Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review Jonathan Aguirre Valadez,1 Ignacio García Juárez,1 Rodolfo Rincón Pedrero,2 Aldo Torre11Department of Gastroenterology, 2Department of Nephrology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico Abstract: Infection with hepatitis C virus (HCV) is highly prevalent in chronic kidney disease (CKD) patients, mainly in those on hemodialysis (HD). The seroprevalence of HCV in developing countries ranges between 7% and 40%. Risk factors for this infection in the CKD population include the number of blood transfusions, duration of end-stage renal disease (ESRD), and prevalence of HCV in HD. Chronic HCV infection in patients with ESRD is associated with an increase in morbidity and mortality in the pre and post kidney transplant periods. The increase in mortality is directly associated with liver complications and an elevated cardiovascular
BACKGROUND: Chronic hepatitis C virus (HCV) infection is associated with increased risk of hepatocellular carcinoma. However, whether HCV infection also increases the risk of extra-hepatic cancer is still not well-established. This systematic review and meta-analysis was conducted in order to investigate the relationship between chronic HCV infection and lung cancer.. MATERIALS AND METHODS: A systematic review was performed using MEDLINE and EMBASE databases from inception to November 2019 with search strategy that included the terms for hepatitis C virus and cancer. Eligible studies must be cohort studies that included patients with chronic HCV infection and comparators without HCV infection, then followed them for incident lung cancer. Relative risk, incidence rate ratio, standardized incidence ratio or hazard risk ratio of this association along with associated 95% confidence interval (CI) were extracted from each eligible study and combined for the calculation of the pooled effect ...
TY - JOUR. T1 - Persistently normal aminotransferase in chronic hepatitis C virus infection. T2 - Is it time to redefine parameters of normality?. AU - Giannini, E.. AU - Testa, R.. PY - 2001. Y1 - 2001. UR - http://www.scopus.com/inward/record.url?scp=0035071120&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0035071120&partnerID=8YFLogxK. M3 - Article. C2 - 11346151. AN - SCOPUS:0035071120. VL - 33. SP - 202. EP - 203. JO - Digestive and Liver Disease. JF - Digestive and Liver Disease. SN - 1590-8658. IS - 2. ER - ...
79036 avhandlingar från svenska högskolor och universitet. Avhandling: Development of vaccines and mouse models for chronic hepatitis C virus infection.
Roches new investigational drug for hepatitis C has been shown to have a strong antiviral effect. The drug, which is known as R1626, has achieved clinically significant reductions in viral load in chronic hepatitis C patients infected with the difficult-to-cure genotype 1 virus.[i] Furthermore, the drop in hepatitis C viral load achieved in patients receiving R1626 is the largest seen for this class of antiviral treatments called polymerase inhibitors. These findings were announced today at the annual meeting for the 57th American Association for the Study of the Liver (AASLD) in Boston ...
Background: Chronic hepatitis C (CHC) patients achieving rapid virological response (RVR) on PEG-IFN/ribavirin (P/R) therapy have high chance of sustained virological response (SVR). To analyze host immunological factors associated with RVR, viral kinetics, phenotype distribution and Th1/Th2 cytokine production by peripheral blood mononuclear cells (PBMC) were studied prior to and during P/R therapy. Methods: TNF-α, IFN-γ, IL-2, IL-6, IL-4 and IL-10 production by PBMC were measured after Toll-like receptor 4 (TLR-4) or phorbol myristate acetate/Ionomycin stimulation in 20 healthy controls and in 50 CHC patients before receiving and during P/R therapy. RVR was achieved by 14, complete early virological response (cEVR) by 19 patients and 17 patients were null-responders (NR). Results: Patients with RVR showed an increased baseline TNF-α and IL-6 production by TLR-4 activated monocytes and increased IFN-γ, decreased IL-4 and IL-10 production by lymphocytes compared to non-RVR patients. SVR was ...
The primary aim of our study was to assess fibrosis and steatosis by quantitative methods in liver biopsy specimens from patients with chronic hepatitis C. Quantification of fibrosis by image analysis has been considered to be the gold standard of morphological measurement because its CV is very low,4, 18 and values have been shown to correlate well with chemical α2 macroglobulin determination.16 Some authors have used morphometric techniques to assess fibrosis in patients with chronic hepatitis C.28, 29 We have shown in a previous study24 that stereology is superior to morphometry for quantifying fibrosis in ALD and NAFLD. In our current study, we have used stereology to assess fibrosis in patients with chronic hepatitis C. Stereological analysis has shown a significant increase in the area fraction with the increase in severity of chronic liver disease.. The modified Ishak scoring system19 has been used by pathologists as a semiquantitative estimation of fibrosis. Other systems have also been ...
Background Hepatitis C virus is mainly transmitted by contact to infected blood. Chronic hepatitis C infection affects around 3% of the world population and progresses slowly. Most patients present without symptoms, or with symptoms like fatigue or liver-related morbidity. Frequently, the disease is discovered by coincidence because of abnormal laboratory results. Around 5% to 40% of all infected patients will develop severe liver damage which can cause severe liver-related morbidities and eventually death. Current treatment consists of pegylated interferon-alpha plus ribavirin and in some subgroups of patients these agents are combined with telaprevir or boceprevir, or other direct acting antivirals. In about 70% of patients with chronic hepatitis C, it is possible to eradicate the virus from the blood, but the clinical effects are not known. Aminoadamantanes (another group of antiviral drugs), mostly amantadine, have been tested in several clinical trials. The authors have previously ...
Thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection is a major problem. The pathophysiology is multifactorial, with auto-immunogenicity, direct bone marrow suppression, hypersplenism, decreased production of thrombopoietin and therapeutic adverse effect all contributing to thrombocytopenia in different measures. The greatest challenge in the care of chronic HCV patients with thrombocytopenia is the difficulty in initiating or maintaining IFN containing anti-viral therapy. Although at present, it is possible to avoid this challenge with the use of the sole Direct Antiviral Agents ( DAAs) as the primary treatment modality, thrombocytopenia remains of particular interest, especially in cases of advanced liver disease. The increased risk of bleeding with thrombocytopenia may also impede the initiation and maintenance of different invasive diagnostic and therapeutic procedures. While eradication of HCV infection itself is the most practical strategy for the remission of
TY - JOUR. T1 - Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. AU - Onaca, Nicholas N.. AU - Levy, Marlon F.. AU - Netto, George J.. AU - Thomas, Mark J.. AU - Sanchez, Edmund Q.. AU - Chinnakotla, Srinath. AU - Fasola, Carlos G.. AU - Weinstein, Jeffrey S.. AU - Murray, Natalie. AU - Goldstein, Robert M.. AU - Klintmalm, Goran B.. PY - 2003/5. Y1 - 2003/5. N2 - The Model of End-Stage Liver Disease (MELD) score, an accurate predictor of mortality in patients awaiting liver transplantation (OLTX), did not predict graft or patient survival in the post-transplant setting. Our aim was to test the model in patients who underwent OLTX for chronic hepatitis C. Two hundred and eighty-seven adult patients who underwent primary OLTX for chronic hepatitis C between December 1993 and September 1999 were studied from a prospectively maintained database. The group was stratified by MELD scores of less than 15, 15-24, and greater than 24. Patient ...
TY - JOUR. T1 - Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C. AU - Murakami, Jun. AU - Shimizu, Yukihiro. AU - Kashi, Yoshiro. AU - Kato, Tsutomu. AU - Minemura, Masami. AU - Okada, Kazuhiko. AU - Nambu, Shuji. AU - Takahara, Terumi. AU - Higuchi, Kiyohiro. AU - Maeda, Yoshinobu. AU - Kumada, Tokimasa. AU - Watanabe, Akiharu. PY - 1999/7/8. Y1 - 1999/7/8. N2 - Intrahepatic lymphoid follicle (ILF) formation is one of the most characteristic and commonly observed histological features in patients with chronic hepatitis C. However, little is known regarding whether follicles in the liver belong to functional lymphoid tissues, where B cells are activated, differentiated, and proliferated, or if the lymphocytes are merely infiltrated after recruitment from the secondary lymphoid organs. To ascertain this possibility, we examined the expression of markers for B-cell activation, differentiation, and proliferation in ILFs in patients with chronic hepatitis C using ...
Serum samples from 139 US patients with chronic hepatitis C virus (HCV) infection were studied using six different genotyping systems, including both molecular and serologic methods, to determine the applicability of these approaches and the prevalence of various HCV subtypes. The concordance of genotyping results based on the various systems (except for core polymerase chain reaction genotyping) was good (93.5%). Subtypes 1a and 1b were prevalent (37.4%). Subtypes 2a (2.2%), 2b (8.6%), and 3a (5.8%) were less common. HCV genotypes could not be determined in 3.4%-16.5% of samples depending on the method used. HCV type 2 was associated with greater histologic activity but lower serum HCV RNA levels (P | .05), whereas type 3 was associated with lower serum alanine aminotransferase levels (P | .05). These data demonstrate a high concordance between HCV genotyping systems and provide a foundation for comparison of genotyping data between studies using different systems. HCV types 1a and 1b are both
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. The geographical prevalence varies considerably in different countries and Scotland is regarded as an area of low risk for the disease. AIMS: To assess the association between chronic hepatitis C infection (HCV) and HCC in a population of patients presenting to a single hospital. PATIENTS: One hundred and fourteen cases of histologically confirmed liver cancer presenting to the Royal Infirmary of Edinburgh between 1985 and 1994 were examined. METHODS: Of 114 cases of HCC, 80 samples of stored sera were available. Samples positive for HCV Ab were genotyped by restriction fragment length polymorphism analysis of HCV c-DNA. A population of 29 cirrhotic patients (diagnosed between 1985 and 1994) with chronic HCV infection was also genotyped. RESULTS: Chronic HCV infection was a major risk factor (30% of tested HCC patients) identified. HCV genotype 1b was predominant (16 of 20 patients). The time from HCV ...
TY - JOUR. T1 - Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. AU - Thompson, Alexander J.. AU - Clark, Paul J.. AU - Singh, Abanish. AU - Ge, Dongliang. AU - Fellay, Jacques. AU - Zhu, Mingfu. AU - Zhu, Qianqian. AU - Urban, Thomas J.. AU - Patel, Keyur. AU - Tillmann, Hans L.. AU - Naggie, Susanna. AU - Afdhal, Nezam H.. AU - Jacobson, Ira M.. AU - Esteban, Rafael. AU - Poordad, Fred. AU - Lawitz, Eric J.. AU - McCone, Jonathan. AU - Shiffman, Mitchell L.. AU - Galler, Greg W.. AU - King, John W.. AU - Kwo, Paul Y.. AU - Shianna, Kevin V.. AU - Noviello, Stephanie. AU - Pedicone, Lisa D.. AU - Brass, Clifford A.. AU - Albrecht, Janice K.. AU - Sulkowski, Mark S.. AU - Goldstein, David B.. AU - McHutchison, John G.. AU - Muir, Andrew J.. PY - 2012/2/1. Y1 - 2012/2/1. N2 - Background & Aims: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 ...
TY - JOUR. T1 - Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. AU - Gutierrez, Julio A.. AU - Lawitz, E. J.. AU - Poordad, F.. PY - 2015/11. Y1 - 2015/11. N2 - The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon-based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all-oral combinations of direct-acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates ,90%, even in patients who failed prior interferon-based triple therapy. In 2015, three all-oral FDA-approved regiments will be available for genotype 1 (sofosbuvir /ledipasvir, sofosbuvir/simeprevir, and paritaprevir/r/ombitasvir/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide ...
The primary objectives of this study are to evaluate safety, efficacy and tolerability of treatment with sofosbuvir (Sovaldi®)/velpatasvir (Epclusa®; SOF/VEL) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection who are on dialysis for End Stage Renal Disease (ESRD).. ...
Patients with chronic hepatitis C and low serum and hepatic iron stores may have an improved response to interferon (IFN). We tested whether iron reduction before and during IFN therapy would lead to an improved sustained biochemical and virological response compared with IFN alone. Eighty-two previously untreated patients with chronic hepatitis C were randomized to either: group A IFN-α2b 3 MU 3 times per week for 6 months, or group B iron reduction before and during IFN-α2b 3 MU 3 times per week for 6 months. Group B patients had lower mean serum alanine transaminase (ALT) levels than group A patients during treatment and follow-up. Group B patients had significantly lower mean hepatitis C virus (HCV)-RNA levels at treatment weeks 4 and 12 (P , .05). Serum HCV RNA was undetectable at the end of treatment in 15 group B patients compared with 7 group A patients (P = .03); 7 group B patients and 3 group A patients had persistently undetectable serum HCV RNA 24 weeks after the end of therapy (P ...
Hospital and four different private clinics in Bahawalpur during 2002 to 2003 Material and Methods: 1. The case record files of 100 patients with chronic hepatitis C vs.100 with chronic hepatitis B were reviewed and the laboratory and demographic data were extracted.2. Anti-HCV and HBsAg were determined for 100 type 2 diabetes patients and 100 healthy adults by ELISA. The diagnosis of diabetes was based on the new WHO criteria. Pearson`s correlation coefficient was calculated and tested for significance Results: 1. The occurrence of diabetes in patients with chronic hepatitis C was 19%, higher than 8% in patients with chronic hepatitis B [ ...
Combination of PEG interferon and ribavirin is the standard treatment of chronic hepatitis C. Efficacy of this treatment has never been evaluated in HCV-HIV infected patients, who have previously been treated with a first line anti-HCV treatment. The purpose of the study is to evaluate the combination PEG interferon alfa2a-ribavirin in HIV-infected patients with chronic hepatitis C pretreated with interferon alone or interferon combined with ribavirin. The patients receive a dose of 180 µg of PEGASYS once a week and 800 to 1200 mg/day of ribavirin (according to weight) for 48 weeks. Primary outcome of the study is a sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti-HCV treatment ...
PubMed journal article Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infectio were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
TY - JOUR. T1 - Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. AU - Zeremski, Marija. AU - Petrovic, Lydia M.. AU - Chiriboga, Luis. AU - Brown, Queenie B.. AU - Yee, Herman T.. AU - Kinkhabwala, Milan. AU - Jacobson, Ira M.. AU - Dimova, Rositsa. AU - Markatou, Marianthi. AU - Talal, Andrew H.. PY - 2008/11/1. Y1 - 2008/11/1. N2 - Chemokines, chemotactic cytokines, may promote hepatic inflammation in chronic hepatitis C virus (HCV) infection through the recruitment of lymphocytes to the liver parenchyma. We evaluated the association between inflammation and fibrosis and CXCR3-associated chemokines, interferon-γ (IFN-γ)-inducible protein 10 (IP-10/CXCL10), monokine induced by IFN-γ(Mig/CXCL9), and interferon-inducible T cell α chemoattractant (I-TAC/CXCL11), in HCV infection. Intrahepatic mRNA expression of these chemokines was analyzed in 106 chronic HCV-infected patients by real-time PCR. The intrahepatic ...
Although several researches have reported the connection between the transforming growth factor-beta 1 (TGF-β1) gene polymorphisms and chronic hepatitis C virus (HCV) infection, the conclusions of these studies were not always consistent. Here, this paper proposed a meta-analysis to evaluate whether the TGF-ß1 gene polymorphisms, −509C/T (rs1800469), codon 10 T/C (rs1982073) and codon 25G/C (rs1800471), were associated with chronic HCV infection. The summary odds ratios (ORs) of chronic HCV infected patients and controls with all SNPs were obtained by adaptive fixed or random effect model. A series of statistical tools were employed to guarantee the accuracy of related pooling ORs, including the Hardy-Weinberg equilibrium (HWE) test, sensitivity analysis and publication bias test. This paper analyzed 18 case-control studies in 17 articles which totally contains 2718 chronic HCV infection cases corresponding to 1964 controls. The results of the meta-analysis indicated that the −509C/T polymorphism
U.S. Food and Drug Administration (FDA) has approved VoseviTM (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated 12 weeks of Vosevi in direct-acting antiviral-experienced chronic HCV-infected patients without cirrhosis or with compensated cirrhosis ...
Many patients with chronic hepatitis C have been treated with interferon (IFN) therapy in Japan, especially after the introduction of subsidies for medical expenses in 2008. However, its performance and outcome have never been evaluated. Therefore, a nationwide, mail-based, retrospective cohort study was conducted. Regional disparities in the demographic features, treatment performance, and virological response were evaluated using an intent-to-treat design. The participating prefectures were classified into nine regions from north to south (Hokkaido/Tohoku, Kanto, Shin-etsu, Hokuriku, Tokai, Kinki, Chugoku, Shikoku, and Kyushu). Multivariate logistic regression analysis was performed to select predictive factors for treatment performance and outcome. From December 2009 to May 2013, 16,854 patients with chronic hepatitis C were registered from 37 prefectures in Japan (median age: 60 years; 50.4 % male; 74.8 % IFN-naïve; HCV genotype [1 or 2]/viral load [high (≥5 log IU/mL) or low (|5 log IU/mL)]: 1
Hepatitis C viral infection can be associated with other infectious diseases including viral and bacterial infections such as tuberculosis. Mycobacterium tuberculosis infection may be latent for many years and revealed during an immunodeficiency state. The responsibility of antiviral treatment in the reactivation of tuberculosis is controversial. We report two cases of tuberculous reactivation during bitherapy with pegylated interferon and ribavirin for chronic hepatitis C. A rapid viral response was obtained in both cases. Tuberculous reactivation occurred at 12 and 13 weeks of antiviral treatment, respectively. Tuberculosis involved urinary tract in one patient and lymph nodes in the other. Antituberculous treatment was given and antiviral treatment maintained. The outcome of tuberculosis was favourable and a sustained viral response was obtained for both patients.
Results. The proportions of patients in each group who were anti-HCV-positive were 35 out of 116 (30%) and 20 out of 115 (17%), respectively. Of the anti-HCV-positive patients, the proportions of HCV RNA-positive patients in each group were 30 out of 35 (86%) and 12 out of 20 (60%), respectively. Levels of ALT activity in patients with HCV infection varied widely for several years after blood transfusion; thereafter ALT activity fell to ,100 IU/L in 2 groups. Serum ALT activity in patients who were HCV RNA-negative became normal. With regard to liver histology, there were no differences in the grade of necroinflammation or stage of fibrosis in patients with different durations of infection or when patients were analyzed according to the presence or absence of malignant disease. Patients mostly had grade 2-4 inflammation and stage 1-2 fibrosis. Thus, chronic hepatitis C was a morphologically mild disease in most children in this study. ...
Background & Aims Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studies evaluating the immunogenicity, tolerance and acceptance of 2009 influenza A vaccine in CHC patients. Methods We evaluated the immunogenicity of influenza A vaccine (Pandemrix®) by using the hemagglutination inhibition (HI) titers method in a well defined cohort of CHC patients receiving or not receiving pegylated-interferon and ribavirin, and compared it with healthy subjects (controls). A group of patients with inflammatory bowel disease (IBD) under immunosuppression, thought to have a lower immune response to seasonal influenza vaccine, were also included as a negative control group. In addition, tolerance to injection site reactions and acceptance was assessed by a validated questionnaire (Vaccinees
The prognosis of chronic hepatitis C virus HCV infection is still ill-defined. The present study prospectively evaluated mortality and complications in a large cohort of patients with chronic hepatitis C. The study included 838 anti-HCV and HCV-RNA-positive patients who were followed for 50.2 26.9 months mean SD ; range, 6-122 months in a...
The prognosis of chronic hepatitis C virus (HCV) infection is still ill-defined. The present study prospectively evaluated mortality and complications in a large cohort of patients with chronic hepatitis C. The study included 838 anti-HCV and HCV-RNA-positive patients who were followed for 50.2 +/- …
This study shows a clear relationship between daily tobacco consumption and the severity of histological activity in patients with chronic hepatitis C. Indeed, the proportion of patients with moderate and marked activity (A2-A3) increased gradually from 62.0% in patients who did not smoke to 81.7% in patients who smoked more than 15 cig/day (p,0.009). As confounding factors, namely alcohol intake, could explain this relationship, a multivariate analysis was performed. It showed that, in addition to two previously identified factors (that is, age over 50 years and alcohol intake exceeding 20 g/day), tobacco consumption higher than 15 cig/day within the six months before biopsy was associated with the severity of histological activity. Thus independent of alcohol intake, tobacco consumption higher than 15 cig/day was associated with aggravation of histological activity in patients with chronic hepatitis C. In our study, both univariate and multivariate analyses showed the relationship between ...
TY - JOUR. T1 - A Decade of Trials of Interferon-Alpha for Chronic Hepatitis C. A Meta-Regression Analysis. AU - Attanasio, Massimo. AU - Tinè, Fabio. AU - Russo, Francesco. PY - 2005. Y1 - 2005. N2 - The most relevant randomized controlled trials of interferon-alpha (IFN) for naive patients with chronic hepatitis C (CHC) published in a decade, just before appearance of pegylated IFN trials in 2000, were included in this paper. Its purpose is to review the relationship between sustained biochemical response in active versus control group versus usual clinical variables as IFN regimens, cirrhosis, genotype and versus less frequently addressed variables as funding, methodological quality or location of principal author. Meta-analysis estimates of global treatment effect varied according to trial design: group 1=IFN versus placebo/no treatment, 32 RCTs, 2499 pts, OR 9.5 (6.3-14.2); group 2a=comparison of IFN schedules, 43 RCTs, 7454 pts, OR 1.6 (1.4-1.9); group 2b=IFN+other drugs versus standard ...
Hepatitis C virus (HCV) infection remains a major global health burden. Hepatitis C causes significant liver-related morbidity and mortality due to hepatic decompensation and development of hepatocellular carcinoma. In addition, extra-hepatic manifestations of hepatitis C are frequent. There is a very large interindividual variability in the natural history of both acute and chronic hepatitis C which can be explained in part by a combination of various host, viral and environmental factors. Successful antiviral treatment can prevent short- and long-term complications of HCV infection in many patients. Still, the relative contribution of distinct risk factors for disease progression in different phases of HCV infection needs to be better defined. Personalized treatment approaches for HCV infection should consider individual risk profiles to avoid both under- and over-treatment - which will remain important also in upcoming era of interferon-free treatment of hepatitis C.
TY - JOUR. T1 - Incresed circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. AU - Lo Iacono, Oreste. PY - 2004. Y1 - 2004. UR - http://hdl.handle.net/10447/23581. M3 - Article. VL - 19. SP - 551. EP - 562. JO - ALIMENTARY PHARMACOLOGY & THERAPEUTICS. JF - ALIMENTARY PHARMACOLOGY & THERAPEUTICS. SN - 0269-2813. ER - ...
Purpose: Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. Methods: Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. Results: Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (,5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, respectively. Seventy percent of discontinuation cases were due to adverse events rather than to laboratory abnormalities. Serious adverse events were rare (,1%). Dose modifications were made in 158 patients (51%) on 237 occasions. After adjusting for covariates, older age was a predictor of early ...
CD209, a c-type lectin expressed by dendritic cells (DCs) acts as a pathogen recognition receptor. A single nucleotide polymorphism (SNP) in the promoter region of CD209 (-336 A/G; rs4804803) affects transcription and is associated with the severity of Tuberculosis and Dengue fever. As CD209 binds Hepatitis C Virus (HCV) glycoprotein-E2, we investigated this SNP in the context of chronic HCV infection. 131 Irish women who had received HCV contaminated Anti-D immunoglobulin and 79 healthy controls were genotyped. We found no association between rs4804803 and the risk of HCV chronicity. However, of those with chronic infection, possession of at least one g-allele was associated with more advanced liver disease, with significantly higher liver fibrosis scores and levels of alanine transaminase (ALT) observed. We conclude that rs4804803, a SNP in the CD209 promoter contributes to the severity of liver disease in chronic HCV infection ...
This is a real-world evidence study that aims to analyze the efficacy, tolerability and safety profile of paritaprevir/ombitasvir/ritonavir and dasabuvir, in patients with renal impairment. We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b. Renal and liver function were assessed at the beginning of therapy, monthly during treatment and three months after therapy completion. All patients achieved sustained virologic response. Common side effects were nausea, fatigue and headache. Close monitoring of tacrolimus blood levels and dose reduction was required in kidney transplant recipients. HCV therapy in the setting of renal dysfunction has always been a challenging topic. Direct-acting antivirals have shown promising effects, demonstrating good tolerance and efficacy in patients with HCV infection and renal impairment. Sustained virologic
Weiland O, Danielsson A, Loof L. Infektionskliniken, Huddinge sjukhus.. The article consists in a brief review of pre-treatment evaluation and antiviral treatment of chronic Hepatitis C (HCV) infection. Patients with viraemia (i.e. HCV RNA seropositive with the PCR technique) should be evaluated historically if they lack contraindications for interferon alpha (IFN-alpha) treatment. Patients with depression, autoimmune and thyroid disorders, decompensated cirrhosis, or solid organ transplants, are ineligible for-IFN-alpha treatment. If the histological evaluation shows moderate to severe chronic hepatitis, and the HCV RNA level is , 3 million Eq/mL serum as measured by bDNA, naive (i.e. formerly untreated) patients should be given an initial 12-week course of IFN-alpha to evaluate treatment response. Those who become HCV-negative should continue the treatment for 48 weeks to increase the likelihood of sustained virological response after treatment cessation. Treatment should be discontinued in ...
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T. and Kumar, R. (2013), Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 57: 2164-2170. doi: 10.1002/hep.26218 ...
This study investigated the effect of pegylated interferon (alfa 2a and alfa 2b) plus ribavirin in chronic hepatitis C patients with mixed genotype 1 and 2.
TY - JOUR. T1 - Low-Dose Cyclosporine A in the Treatment of Severe Atopic Dermatitis Complicated by Chronic Hepatitis C Virus Infection. AU - De Simone, Clara. AU - Garcovich, Simone. AU - Gnarra, Maria. AU - Garcovich, Matteo. PY - 2017. Y1 - 2017. N2 - Atopic dermatitis (AD) is the most frequent chronic inflammatory skin disorder in children and is usually accompanied by genetic and environmental factors. Effective management and treatment of AD is challenging and often requires systemic immunosuppressive therapy when refractory to topical treatments. We report a rare association between chronic hepatitis C virus (HCV) and severe AD, management of which required systemic cyclosporine because of its favorable effects on inflammatory and viral-related clinical outcomes.. AB - Atopic dermatitis (AD) is the most frequent chronic inflammatory skin disorder in children and is usually accompanied by genetic and environmental factors. Effective management and treatment of AD is challenging and often ...
MARTINS, Ronaldo Soares; MACHADO, Juliano Antunes e TEIXEIRA, Rosângela. Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a. Rev. Soc. Bras. Med. Trop. [online]. 2012, vol.45, n.5, pp.655-656. ISSN 0037-8682. https://doi.org/10.1590/S0037-86822012000500023.. The treatment of chronic hepatitis C has frequent side effects such as cytopenias and neuropsychiatric symptoms. However, pulmonary toxicity associated with interferon is rarely described. This paper describes the clinical case of a 67-year-old female patient with chronic hepatitis C who presented an acute onset of dry cough, dyspnoea, and fever 36 weeks after the use of pegylated interferon alfa-2a and ribavirin. The lung biopsy confirmed the diagnosis of a bronchiolitis obliterans organizing pneumonia (BOOP). Corticotherapy was initiated, with clinical and radiological improvement. This paper aims to advise physicians to this occasional, though severe, ...
TY - JOUR. T1 - Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. AU - Okada, Kyoko. AU - Furusyo, Norihiro. AU - Ogawa, Eiichi. AU - Ikezaki, Hiroaki. AU - Ihara, Tsuyoshi. AU - Hayashi, Takeo. AU - Kainuma, Mosaburo. AU - Masayuki, Murata. AU - Hayashi, Jun. PY - 2013/2/1. Y1 - 2013/2/1. N2 - The association between HCV infection and myocardial disorders remains unclear. This study aimed to assess whether or not HCV infection influences myocardial dysfunction by the use of NT-proBNP, a sensitive marker of myocardial dysfunction. A total of 198 participants [99 patients with chronic HCV infection (aged 46-68 years) and 99 anti-HCV-negative sex and age matched controls] were examined. Serum HCV-RNA level and HCV genotype were tested and liver biopsy was done only for the patient group. The NT-proBNP concentration of the HCV patients (mean 71.6 ± 79.1 pg/ml; median 46.0 pg/ml, range 5.0-400.0) was significantly higher ...
Background: About 25% of patients with chronic hepatitis C virus (HCV) infection have persistently normal alanine aminotransferase (ALT) values (1). No agreement about management of these patients exists (2). The standard of care for chronic HCV infection is the combination of peginterferon plus ribavirin, and the addition of amantadine may increase the virologic response (3, 4). However, optimal treatment in patients with persistently normal ALT levels has not been investigated ...
BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.OBJECTIVE: To study the efficacy and safety of a novel 20 kD pegylated interferon alpha-2a derived from |i|Hansenula polymorpha|/i| in combination with ribavirin for the treatment of Egyptian patients with genotype 4 chronic hepatitis C (CHC).METHODS: One hundred seven patients with genotype 4 CHC were involved in the present study. Liver biopsy was performed in all patients. All patients received a fixed weekly dose of 160 μg of a novel pegylated interferon in combination with ribavirin in standard and adjusted doses. Serum HCV RNA levels were assessed by a real-time sensitive polymerase chain reaction assay at four, 12, 48 and 72 weeks after the start of therapy. Patients demonstrating an early virological response (EVR) completed a 48-week course of treatment.RESULTS: The overall sustained virological response (SVR) was 60.7%. The SVR in patients with a rapid virological
Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis. Clin Res Hepatol Gastroenterol. 2013 Feb; 37(1):41-6 ...
Background/Aims: In chronic hepatitis C, disease progression and clinical manifestations are heterogenous. To clarify the role and interactions of viral and host factors in inducing liver cell injury, we examined the associations of several virological and metabolic variables with serum alanine aminotransferase levels. Methods: Patients with chronic hepatitis C enrolled in three phase III clinical trials of peginterferon alfa-2a (40KD) plus ribavirin (two studies analysing elevated and one persistently normal alanine aminotransferase) were included. Results: Multivariate analyses of 2881 patients before treatment and of 1403 patients with a sustained virological response indicated that gender, viral factors (genotype, HCV RNA titer) and indicators of metabolic syndrome (body mass index, blood pressure, blood glucose, cholesterol and triglyceride concentration) were associated with alanine aminotransferase levels. In addition, hepatitis C virus infection influenced serum lipids concentration ...
Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection. HIV-infected Taiwanese patients with acute HCV infection received peginterferon plus weight-based ribavirin for 24 weeks (n = 24), and those with chronic HCV genotype 1 or 6 (HCV-1/6) and HCV genotype 2 or 3 (HCV-2/3) infection received response-guided therapy for 12-72 and 24-48 weeks, respectively (n = 92). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy. The SVR rates were 83% and 72% in patients with acute and chronic HCV infection (p = 0.30), and 68% and 72% in patients with chronic HCV-1/6 and HCV-2/3 infection (p = 0.48), respectively. While no factors predicted SVR in acute HCV and chronic HCV-2/3 infection, age (odds ratio [OR] per 1-year increase: 0.88, 95% confidence interval [CI]: 0.78-0.99, p = 0.04), HCV RNA (OR per 1-log10 increase: 0.18, 95% CI: 0.03-0.98, p = 0.03), ...
Direct-acting antivirals (DAAs) result in a highly sustained virological response rate and better patient tolerance. However, this therapeutic approach may, on rare occasions, give rise to psychiatric symptoms. We describe a case requiring discontinuation of DAA and ribavirin combination therapy due to psychiatric symptoms in a patient with congenital anxious personality traits. The information summarized here will be helpful to physicians treating chronic hepatitis C virus (HCV) infection in patients with underlying psychiatric problems. A 57-year-old Japanese woman diagnosed with chronic HCV infection was prescribed DAA and ribavirin combination therapy. She had a history of mild innate anxiety and development of psychiatric symptoms due to interferon (IFN) therapy 8 years prior, which subsided with discontinuation of the therapy. Similar psychiatric symptoms such as enervation, palpitations, an episode of hyperventilation, and consciousness disturbances with myotonia were observed after the
Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprot ...
Peginterferon Alfa-2B Versus Peginterferon Alfa-2A With Ribavirin for the Treatment of Chronic Hepatitis C: The Pursuit of an Ideal
Related Queries:. ribavirin prospect ribavirin porphyria interferon v�™ ribavirin ribavirin gallbladder interferon and ribavirin hepatitis b ribavirin interferon therapy ribavirin nrti ribavirin psychiatric ribavirin cp ribavirin rna ribavirin in chronic hepatitis c past and future oral ribavirin hepatitis c rebetol label ribavirin back pain ribavirin inhalation administration ribavirin interferon alfa2b recombinant side effects ribavirin fiyat�� ribavirin and fat ribavirin drinking alcohol mechanism of action of ribavirin in the combination treatment of chronic hcv infection viral pneumonia ribavirin pegylated interferon ribavirin therapy hepatitis c causing cataract ribavirin dosage hepatitis c ribavirin monotherapy hepatitis rebetol ribavirin price ribavirin angioedema ribavirin injection stability. ...
Viral Hepatitis C American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA): Recommendations for Testing, Managing, and Treating Hepatitis C: HVC Testing and Linkage to Care. American Association for the Study of Liver Diseases (AASLD)and Infectous Diseases Society of America (IFDA). San Francisco, CA. 2014. Available from URL: http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. As accessed 2014-02-05.. Workowski KA, Berman S, & Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1-110.. Yee HS, Chang MF, Pocha C, et al: Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107(5):669-689.. Flamm SL.: Chronic hepatitis C virus infection. . JAMA. , 2003; ...
Background & Aims:. Sustained response to interferon treatment for chronic Hepatitis C is unsatisfactory, This study examined whether combining interferon alfa with ribavirin induces a better sustained efficacy than interferon alone in the treatment of chronic Hepatitis C.. Methods:. Sixty noncirrhotic patients with chronic Hepatitis C were randomly assigned to three groups, Group 1 received 1200 mg oral ribavirin daily plus 3 million units of recombinant interferon alfa 2a thrice weekly for 24 weeks, group 2 received the same dose of interferon alfa 2a alone for 24 weeks, and group 3 received no treatment, The patients were then followed up for an additional 96 weeks.. ...
Prison and its Medical Provider Ignore Center for Disease Control and Prevention (CDC) Standards of Care. St. Louis - A federal judge has certified that a lawsuit challenging the Missouri Department of Corrections (MDOC) systematic denial of medication to inmates with chronic Hepatitis C (HCV) can move forward as a class action.. The lawsuit was filed by the Roderick and Solange MacArthur Justice Center - St. Louis (MJC-STL) and the ACLU of Missouri (ACLU) on behalf of three individual Plaintiffs incarcerated at the MDOC, all of whom have been consistently refused adequate treatment for years.. We are grateful to the court of allowing us to move forward with our suit. The designation of the class is an important step in forcing the Missouri Department of Corrections to treat inmates with chronic Hepatitis C according to the universally recognized medical standards, said Tony Rothert, Legal Director for ACLU. That inmates are forced to beg for life-saving treatment, only to be repeatedly ...
Hellenic Society of Gastroenterology. Annals of Gastroenterology.Journal part.Scientific article.Article.2016 . Creators: Nabeel, Mohammed M., Zakaria, Zeinab, Mobarak, Lamiaa, Omran, Dalia, Hassan, Ehsan.Background Hepatitis C virus is a worldwide problem. Noninvasive methods for liver fibrosis assessment as ultrasound-based approaches have emerged to replace liver biopsy. The aim of this study was to evaluate the diagnostic accuracy of real-time elastography (RTE) in the assessment of liver fibrosis in patients with chronic hepatitis C (CHC), compared with transient elastography and liver biopsy.Methods RTE, FibroScan and liver biopsy were performed in 50 CHC patients. In addition, aspartate aminotransferase to platelet ratio index (APRI) and routine laboratory values were included in the analysis.Results RTE was able to diagnose significant hepatic fibrosis (F ≥2) according to METAVIR scoring system at cut-off value of 2.49 with sensitivity 100%, specifi city 66%, and area under the receiver
Background and Aims: Having a body mass index above or equal to 30 kg/m2 in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.. Methods: This study evaluated impact of obesity on outcome as well as interferon and ribavirin concentrations following standard-of-care fixed dosing with peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily among 303 HCV genotype 2/3-infected patients enrolled in the per-protocol analysis of a recently completed phase III trial (NORDynamIC).. Results: Patients with BMI ≥30 kg/m2 showed poorer outcome following 24 weeks of therapy (SVR 62% vs. 89% for BMI ≥30 vs. ,30; P = 0.006) along with significantly higher steatosis grade (P = 0.002), HOMA-IR (P,0.0001), triglyceride levels (P = 0.0002), and baseline viral load (P = 0.028). Obesity was also significantly associated ...
1. Huang, H., Shiffman, M.L., Friedman, S., Venkatesh, R., Bzowej, N., Abar, O.T., et al., A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C, Hepatology, 2007, vol. 46, no. 2, pp. 297 306. https://doi.org/10.1002/hep.21695 2. Li Yonghong, Monica Chang, Olivia Abar, Veronica Garcia, Charles Rowland, Joseph Catanese, David Ross, Samuel Broder, Mitchell Shiffman, Ramsey Cheung, Teresa Wright, Scott L. Friedman, and John Sninsky, Multiple variants in Toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection, J. Hepatol., 2009, vol. 51, no. 4, pp. 750 757. https://doi.org/10.1016/j.jhep.2009.04.027 3. Hishida, A., Matsuo, K., Goto, Y., Naito, M., Wakai, K., Tajima, K., and Hamajima, N., Combined effect of miR-146a rs2910164 G/C polymorphism and Toll-like receptor 4 +3725 G/C polymorphism on the risk of severe gastric atrophy in Japanese, Digest. Dis. Sci., 2011, vol. 56, no. 4, pp. 1131 1137. ...
Thrombocytopenia, encountered frequently among patients with HCV-related chronic hepatitis and cirrhosis, is usually aggravated during IFN-based antiviral therapy. In several large-scale clinical trials, the incidence of severe on-treatment thrombocytopenia was 3-5% among all patients with chronic hepatitis C [2-4]. In the current study, severe thrombocytopenia occurred more frequently (12.8%) in patients with baseline thrombocytopenia. Roomer et al. (2010) documented that patients with baseline thrombocytopenia were vulnerable to severe thrombocytopenia [5]. This group also found that severe thrombocytopenia was significantly associated with bleeding events. In the present study, severe thrombocytopenia did occur in some patients during antiviral therapy, but it was not followed by mortality or major morbidity. Instead, severe thrombocytopenia was associated with higher rates of premature discontinuation of therapy.. Thrombocytopenia is one of the extrahepatic manifestations of HCV infection. ...
This study was designed to investigate the impact of liver cirrhosis due to chronic hepatitis C virus (HCV) infection on the disease-free and overall survival of ovarian cancer patients undergoing a standard primary operation followed by standard chemotherapy. Attainment of the operative goals, intra- and postoperative events, possible complications under chemotherapy necessitating the termination of treatment, and the impact of ovarian cancer treatment on liver function were assessed. This was a prospective observational study that included only patients with primary epithelial ovarian cancer. Only patients with Child-Turcotte-Pugh classification class A disease were recruited. Patients were divided into two groups according to whether they had liver cirrhosis. All the patients underwent primary debulking surgery followed by 6 cycles of chemotherapy, and were followed-up for 24 months after chemotherapy was completed. We recruited 77 patients, 19 of whom had liver cirrhosis. There were no significant
Introduction: The interleukin 28B (IL28B) genotype is associated with changes of lipid metabolism in patients infected with hepatitis C virus (HCV). The association of steatosis with serum levels of adiponectin in chronic hepatitis C (CHC) patients has also been documented. This study aimed for the evaluation of serum levels of IL28B and adiponectin as well as the association of IL28B SNPs with different clinicopathological parameters in HCV-infected patients.. Methodology: All 142 HCV-infected patients received peg-interferon plus ribavirin. Detection of rs8099917 and rs12979860 IL-28B genotypes was done with specific primers. Serum IL28 and adiponectin levels were measured using commercial ELISA kits.. Results: Higher levels of both IL28 and adiponectin were found in patients. In Genotype 3a (G3a) -infected patients, IL28 and adiponectin serum levels were significantly higher than those infected with G1a. A correlation was found between increasing levels of AST and ALT in G3a-infected patients ...
The recognition of early predictors of a lack of sustained response in HIV-infected patients receiving peg-IFN plus ribavirin may allow the earlier discontinuation of a medication that will not provide benefit while frequently being associated with side-effects, is expensive, reduces the patients quality of life, and as stated earlier, may be harmful because of interactions between ribavirin and HIV nucleoside analogues. No data are available so far on the best time for discontinuing therapy in HIV/HCV-co-infected patients receiving peg-IFN plus ribavirin. In our trial, we specifically examined whether the recognition of negative serum HCV-RNA levels at different timepoints could be used for early therapy-off decision-making. The time to the first negative serum HCV-RNA levels among subjects who later achieved sustained responses was one month in 72% of cases, and 3 months in 88%. However, three of the 27 subjects (11.1%) who finally reached sustained response cleared HCV-RNA after the third ...
In the early stages of infection, most hepatitis C patients do not receive treatment, either because the virus remains undiagnosed as it is mistaken for flu, or because treatment is not necessary.. However, if hepatitis C becomes chronic and starts to affect liver function, treatment is necessary. Conventional hepatitis C treatments are available with varying success, depending on the type of virus contracted. Alternative hepatitis C treatments are also available, again with varying degrees of proven success.. The Functional Medicine approach to Hepatitis C is an alternative Hepatitis C treatment program that supports the bodys immunity and addresses the overall health and wellbeing of the patient, maximizing success rates and restoring the patients health without the painful and distressing side effects commonly experienced in conventional treatment.. If treatment of hepatitis C is not successful, the condition may worsen over a period of years and a liver transplant may be necessary. It is, ...
Introduction: Insulin resistance (IR) is documented in patients with chronic hepatitis C(CHC), plays an important factor in disease progression and predicting poor response to treatment. In chronic liver disease, levels of insulin-like growth factor-1 (IGF-1) were correlated with IR. Aim: To evaluate IR and serum levels of IGF-1 in Egyptian patients with CHC after anti-viral therapy. Patients and Methods: Forty biopsy-proven, non-diabetic, CHC patients, who received combined IFN/ribavirin therapy, in addition to 10 healthy controls were studied. Serum levels of IGF-1, growth hormone (GH) were measured and HOMA-IR(homeostasis model assessment of IR), body mass index (BMI) were calculated. Baseline data, retrieved from patients files before initiation of therapy, together with response to antiviral therapy were analyzed with respect to the measured variables. Results: All patients possessed a significant higher HOMA-IR score (p = 0.02), GH levels (p < 0.001) and blood glucose levels (p < 0.001) than
© 2016 European Association for the Study of the Liver. Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcomes in treated and untreated patients with decompensated cirrhosis. Methods Patients with HCV and decompensated cirrhosis or at risk of irreversible disease were treated in an expanded access programme (EAP) in 2014. Treatment, by clinician choice, was with sofosbuvir, ledipasvir or daclatasvir, with or without ribavirin. For functional outcome comparison, untreated patients with HCV and decompensated cirrhosis who were registered on a database 6 months before treatment was available were retrospectively studied. Primary endpoint was sustained virological response 12 weeks post antiviral treatment (treated cohort) and the secondary endpoint (both cohorts) was adverse outcomes (worsening in MELD score or serious adverse event) within 6 months. Results 467
Background: The rate of progression to cirrhosis varies among individuals chronically infected with the hepatitis C virus (HCV). Coagulation pathway activation in models of hepatic fibrosis suggests variation in coagulation pathway components may influence the rate of fibrosis. We hypothesised that polymorphisms of the coagulation factors II and V affect the rate of progression to cirrhosis in HCV infected subjects. Methods: We studied the relationship between rate of fibrosis (calculated by dividing the fibrosis stage by duration of infection) and genotypes of specific coagulation pathway genes in 352 White European patients infected with HCV. Genotyping was performed using reverse line blot hybridisation. Results: The rate of fibrosis was significantly higher in patients with the factor V Leiden genotype (Arg560Gln) (ANOVA, p=0.004). In disease association studies, o significant association was seen (Fishers exact test, p=0.029; odds ratio 3.28 for fast progression to cirrhosis (expected to reach
Study: Cannabis Use Associated With Reduced Likelihood of Liver Cirrhosis Among Hepatitis C Patients | NORML SALEM, MA - Hepatitis C patients who use cannabis are less likely to contract liver cirrhosis as compared to matched controls, according to clinical data published in the Canadian Journal of Gastroenterology & Hepatology. A team of researchers from the United States and Canada assessed the effect of cannabis use on chronic liver disease in a cohort of Study: Cannabis Use Associated With Reduced Likelihood of Liver Cirrhosis Among Hepatitis C Patients | The Daily Chronic http://www.thedailychronic.net/2018/92235/study-cannabis-use-associated-reduced-likelihood-liver-cirrhosis-among-hepatitis-c-patients/
Hepatitis C virus is a global health concern, estimated to infect 2-3% of the worlds population. Inter-individual differences in the course of infection and response to therapy, highlighted by recent genomewide association studies, point to the crucial role of the host immune system in the efficient control of infection. Ongoing progress in the studies of the role of innate immunity during hepatitis C virus infection has improved our understanding of the intricacies of the host-virus interactions. In this review, we summarize and discuss the current knowledge concerning interferon signaling in the liver during acute and chronic hepatitis C virus infection and its implications for the outcome of interferon-alpha-based antiviral therapies ...
An enzyme linked immunosorbent assay has been recently developed which detects and distinguishes between infections with the three major hepatitis C virus (HCV) genotypes prevalent in Europe. Using this assay we have investigated the sera of 30 Italian and 37 Spanish children with chronic hepatitis C. Infection with HCV type 1 was found in 43% of Italian and 46% of Spanish children. Of the Italian children 7% were infected with HCV of type 2 and 7% had a mixed type 1/type 2 serotype. Infection with HCV type 3 was found in 7% of Italian and 8% of Spanish children while 36% of Italian and 46% of Spanish children had non-reactive sera. Serotype 3 was significantly more frequent in children with anti-HCV positive mothers (often drug abusers) than in those with percutaneous exposure (25% vs. 2%, p | 0.05). Mean alanine aminotransferase values were significantly higher in children with HCV type 1 than in those with non-reactive sera (P | 0.05). These results indicate a similar distribution of HCV serotypes in
European guidelines have not recommended hepatitis C interferon therapy for hepatitis C - Sohu health over the past two years because of a variety of direct antiviral drugs listed, completely changed the hepatitis C virus infection antiviral treatment strategy, the treatment of hepatitis C in interferon free shorter course and better curative effect and less side effects, a wide selection of all oral treatment time. Since 2015, the European guidelines no longer recommend the use of low virological response and drug side effects of interferon or pegylated interferon combined with ribavirin, also use the first generation protease inhibitor bosai kpwe and Trapp Wei is not recommended. C Guide 2015 Europe also recommended treatment combined with Sago kpwe pegylated interferon and ribavirin, as more antiviral drugs for the treatment of hepatitis C listed since 2016, with all disappeared from the interferon program guide. In 2016 the European guidelines recommend different HCV genotypes of hepatitis C ...
Hepatitis C - Animation Hepatitis C is a viral disease that leads to swelling or inflammation of the liver. If youve been diagnosed with hepatitis C, you may be worrying about your health. Lets answer some questions you may have about hepatitis C. Hepatitis C is irritation and swelling of the liver from infection with the hepatitis C virus. You can get hepatitis C if you have been on long-term kidney dialysis, or have regular contact with blood at work such as a health care worker, have unprotected sex with someone infected with hepatitis C, use injected street drugs or share a needle with someone who has hepatitis C, received a tattoo or acupuncture from contaminated instruments, although the risk is low with licensed, commercial tattoo shops, received blood or organs from a donor who has hepatitis C, share a toothbrush or razors with someone who has the disease, or were born to a mother infected with hepatitis C. Most people newly infected with hepatitis C virus will not have symptoms. About ...
GLOBAL GENOTYPE DISTRIBUTION OF HEPATITIS C VIRAL INFECTION AMONG PEOPLE WHO INJECT DRUGS Bielen R1,2, Robaeys G1,2,3, Azar DA2,3, Razavi H4, Nevens F3 1Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium 2Department of Gastro-Enterology and Hepatology, ZOL Genk, Belgium 3Department of Gastro-Enterology and Hepatology, KULeuven, Belgium 4Center for disease analysis, Louisville, USA Background: Hepatitis C viral infection (HCV) after injection drug use is very prevalent. HCV genotypes are clinically significant as they are relevant to vaccine development, the evolution to fibrosis and cirrhosis and the response to antiviral treatment. Thus, the HCV genotype, including genotype 1 subtype, should be assessed prior to treatment initiation. However, no systematic review update on the global genotype distribution of HCV in people who inject drugs (PWID) is available at this moment. Method: A systematic review was performed by using the keywords: Genotype, Hepatitis C, Injection ...
Hepatitis C virus, which infects the liver and certain immune cells, leads to serious liver diseases such as cirrhosis and liver cancer more frequently than any other form of hepatitis. HCV is an RNA virus known to undergo a high rate of mutation that may help it both to avoid control by the immune system and to develop resistance to direct antiviral medications. According to the World Health Organization, HCV infects approximately 170 million people worldwide, including at least 2.7 million in the United States, and 10-20 percent of those chronically infected with HCV will ultimately develop liver cirrhosis, making HCV the leading cause of liver transplants in the United States. The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually from HCV-related cirrhosis or liver cancer. Coley believes, there is an unmet need for therapies with better side effect profiles and equivalent or superior efficacy, especially in the difficult-to-treat population of ...
TY - JOUR. T1 - Limited Generalizability of Registration Trials in Hepatitis C. T2 - A Nationwide Cohort Study. AU - Berden, Floor A C. AU - de Knegt, Robert J. AU - Blokzijl, Hans. AU - Kuiken, Sjoerd D. AU - van Erpecum, Karel J L. AU - Willemse, Sophie B. AU - den Hollander, Jan. AU - van Vonderen, Marit G A. AU - Friederich, Pieter. AU - van Hoek, Bart. AU - van Nieuwkerk, Carin M J. AU - Drenth, Joost P H. AU - Kievit, Wietske. PY - 2016. Y1 - 2016. N2 - BACKGROUND: Approval of drugs in chronic hepatitis C is supported by registration trials. These trials might have limited generalizability through use of strict eligibility criteria. We compared effectiveness and safety of real world hepatitis C patients eligible and ineligible for registration trials.METHODS: We performed a nationwide, multicenter, retrospective cohort study of chronic hepatitis C patients treated in the real world. We applied a combined set of inclusion and exclusion criteria of registration trials to our cohort to ...